<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005802</url>
  </required_header>
  <id_info>
    <org_study_id>1380.00</org_study_id>
    <secondary_id>FHCRC-1380.00</secondary_id>
    <secondary_id>NCI-H00-0057</secondary_id>
    <secondary_id>CDR0000067777</secondary_id>
    <nct_id>NCT00005802</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia</brief_title>
  <official_title>Chemotherapy (CT) Followed by Donor Lymphocyte Infusion (DLI) Plus Interleukin 2 (IL-2) for Patients With Relapse Acute Myeloid or Lymphoid Leukemia After Allogeneic Hematopoietic Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill&#xD;
      leukemia cells. Treating donor white blood cells with interleukin-2 in the laboratory may&#xD;
      help them kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of interleukin-2&#xD;
      when given after chemotherapy and donor white blood cells and to see how well they work in&#xD;
      treating patients with acute myeloid leukemia or acute lymphoid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of interleukin-2 following donor lymphocyte&#xD;
           infusion and chemotherapy in patients with relapsed acute myeloid or lymphoid leukemia&#xD;
           after allogeneic peripheral blood stem cell transplantation.&#xD;
&#xD;
        -  Determine the toxicity and efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of interleukin-2 (IL-2). Patients are stratified&#xD;
      according to disease status after chemotherapy (acute myeloid leukemia (AML) in complete&#xD;
      remission (CR) vs acute lymphoid leukemia (ALL) or AML not in CR).&#xD;
&#xD;
      Patients receive one of three induction chemotherapy regimens, depending on type of leukemia,&#xD;
      prior treatment, and response.&#xD;
&#xD;
        -  Regimen 1: Patients receive high dose cytarabine IV over 2 hours twice a day on days 1,&#xD;
           3, and 5.&#xD;
&#xD;
        -  Regimen 2: Patients receive mitoxantrone IV over 15 minutes and etoposide IV over 30&#xD;
           minutes on days 1-5.&#xD;
&#xD;
        -  Regimen 3: Patients receive fludarabine IV over 30 minutes on days 1-5, cytarabine IV&#xD;
           over 2 hours on days 1-4, and filgrastim (G-CSF) subcutaneously beginning on day 1 and&#xD;
           continuing until blood counts recover.&#xD;
&#xD;
      Patients with extramedullary relapse receive local radiotherapy. Patients with ALL or CNS&#xD;
      relapse receive intrathecal methotrexate with or without hydrocortisone and cytarabine.&#xD;
&#xD;
      Patients receive one donor lymphocyte infusion IV over 15-30 minutes within 28-60 days after&#xD;
      starting chemotherapy. On the same day, IL-2 IV is administered over 24 hours for 5 days.&#xD;
      After 2 days rest, IL-2 is again administered continuously for 10 days.&#xD;
&#xD;
      Cohorts of 5 patients receive escalating doses of IL-2 until the maximum tolerated dose (MTD)&#xD;
      is determined. The MTD is defined as the dose at which no more than 2 of 5 patients&#xD;
      experience dose limiting toxicities. Up to 40 patients are treated at the MTD.&#xD;
&#xD;
      Patients are followed monthly for 3 months, and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 11-15 patients per year will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1999</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Relapsed acute myeloid leukemia or acute lymphoid leukemia after allogeneic peripheral&#xD;
             blood stem cell transplantation (PBSCT), documented by 1 of the following:&#xD;
&#xD;
               -  Morphologic relapse defined as 1 or more of the following:&#xD;
&#xD;
                    -  Peripheral blasts in absence of growth factor therapy&#xD;
&#xD;
                    -  Bone marrow blasts greater than 5% of nucleated cells&#xD;
&#xD;
                    -  Extramedullary (CNS, testicular, or other sites)&#xD;
&#xD;
               -  Flow cytometric relapse defined as appearance in peripheral blood or bone marrow&#xD;
                  of cells with abnormal immunophenotype consistent with leukemia recurrence and&#xD;
                  noted at pretransplant&#xD;
&#xD;
               -  Cytogenetic relapse defined as:&#xD;
&#xD;
                    -  Appearance in 1 or more metaphases from bone marrow or peripheral blood&#xD;
                       cells of nonconstitutional cytogenetic abnormality noted in at least 1&#xD;
                       cytogenetic study performed prior to transplant OR&#xD;
&#xD;
                    -  New abnormality known to be associated with leukemia&#xD;
&#xD;
          -  Allogeneic PBSCT from related (HLA identical and 1 antigen mismatch) OR unrelated&#xD;
             (match) donor&#xD;
&#xD;
               -  Must have achieved complete remission after PBSCT&#xD;
&#xD;
          -  Current donor must be same as prior donor&#xD;
&#xD;
               -  Age 10 and over&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No congestive heart failure requiring diuretics&#xD;
&#xD;
          -  No uncontrolled arrhythmia&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary dysfunction requiring oxygen therapy&#xD;
&#xD;
          -  No pneumonia or severe obstruction&#xD;
&#xD;
          -  FEV_1 at least 50% of predicted OR no greater than 50% decline from baseline&#xD;
&#xD;
          -  No severe restrictive lung disease (total lung capacity less than 60% or 50% declined&#xD;
             from baseline) not due to leukemia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No sepsis, aspergillosis, or other active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent cyclosporine or tacrolimus during induction chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary E. D. Flowers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

